Cover Image

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD, specifically evaluating nivolumab plus rucapari...

Full description

Saved in:
Bibliographic Details
Main Authors: Fizazi, Karim (Author) , Retz, Margitta (Author) , Petrylak, Daniel P. (Author) , Goh, Jeffrey C. (Author) , Perez-Gracia, Jose (Author) , Lacombe, Louis (Author) , Zschäbitz, Stefanie (Author) , Burotto, Mauricio (Author) , Mahammedi, Hakim (Author) , Gravis, Gwenaelle (Author) , Bastos, Diogo Assed (Author) , McCune, Steven L. (Author) , Limón, Juan Carlos Vázquez (Author) , Kwan, Edmond M. (Author) , Castellano, Daniel (Author) , Fléchon, Aude (Author) , Saad, Fred (Author) , Grimm, Marc-Oliver (Author) , Shaffer, David R. (Author) , Armstrong, Andrew J. (Author) , Bhagavatheeswaran, Prabhu (Author) , Amin, Neha P. (Author) , Ünsal-Kaçmaz, Keziban (Author) , Wang, Xuya (Author) , Li, Jun (Author) , Loehr, Andrea (Author) , Pachynski, Russell K. (Author)
Format: Article (Journal)
Language:English
Published: 17 August 2022
In: Journal for ImmunoTherapy of Cancer
Year: 2022, Volume: 10, Issue: 8, Pages: 1-14
ISSN:2051-1426
DOI:10.1136/jitc-2022-004761
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1136/jitc-2022-004761
Verlag, kostenfrei, Volltext: https://jitc.bmj.com/content/10/8/e004761
Get full text
Author Notes:Karim Fizazi, Margitta Retz, Daniel P. Petrylak, Jeffrey C. Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L. McCune, Juan Carlos Vázquez Limón, Edmond M. Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc-Oliver Grimm, David R. Shaffer, Andrew J. Armstrong, Prabhu Bhagavatheeswaran, Neha P. Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K. Pachynski
Description
Summary:Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD, specifically evaluating nivolumab plus rucaparib.
Item Description:Gesehen am 22.11.2022
Physical Description:Online Resource
ISSN:2051-1426
DOI:10.1136/jitc-2022-004761

Similar Items